| Serial Number | 97117501 |
| Word Mark | PRECISION BIOSCIENCES |
| Filing Date | Wednesday, November 10, 2021 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, April 25, 2023 |
| Registration Number | 7034223 |
| Registration Date | Tuesday, April 25, 2023 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, December 20, 2022 |
| Goods and Services | pharmaceutical preparations, namely, cell therapy products utilizing t-cell therapy for use in treating disease; cell-based immunotherapeutic treatment by way of genetically modified cells for use in human therapeutics and the treatment of cancer; pharmaceuticals for the treatment of cancer; pharmaceutical preparations in the nature of genetically modified cells, namely, genetically modified immune cells for use in human therapeutics and in the treatment of cancer; pharmaceutical and biological preparations based on gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy for use in human therapeutics, namely, therapeutic pharmaceuticals developed through genome modifications for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological, hematologic and viral diseases and disorders; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications, namely, antifungal preparations, dermatological preparations, smoking cessation preparations and tissue repair preparations; engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, CAR T-cell preparations, T-cell preparations, B-cell preparations, Treg preparations, and NK cell preparations, all for clinical use, medical use, clinical laboratory use, and medical laboratory use |
| Goods and Services | genome editing reagents for research purposes; Chemical, biochemical, biotechnological products intended for industry, agriculture, horticulture, namely, polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors; chemical, biochemical, biotechnological and bacteriological products intended for research laboratories and control laboratories, namely, polypeptides for in vivo and in vitro genetic engineering; Biochemicals and biologics, namely, engineered proteins for gene regulation, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, gene modification, and gene correction, all for use in scientific research, pharmaceutical research, agricultural biotechnology, diagnostics, and industrial biotechnology; engineered proteins for use in scientific research and analysis relating to genetic diseases, gene therapy, and cell therapy; biochemicals and biologics, namely, engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, CAR T-cell preparations, T-cell preparations, B-cell preparations, Treg preparations, and NK cell preparations, all for use in scientific research and analysis and diagno |
| Goods and Services | Medical services, namely, cellular immunotherapy treatments utilizing chimeric antigen receptor t cells for use in treating disease, namely, the treatment of cancer |
| Disclaimer with Predetermined Text | "BIOSCIENCES" |
| Goods and Services | research in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic disease, gene therapy and cell therapy; pharmaceutical research and development services; Scientific research; scientific research in genetic, medical, pharmaceutical and veterinary fields; scientific research in chemistry, biology, biochemistry, molecular biology, bacteriology; scientific analysis in the field of immunotherapy; scientific research in the field of cellular immunotherapy utilizing chimeric antigen receptor t cells for use in treating cancer |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, November 17, 2021 |
| Primary Code | 001 |
| First Use Anywhere Date | Monday, February 11, 2008 |
| First Use In Commerce Date | Monday, February 11, 2008 |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, November 17, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | Thursday, February 25, 2016 |
| First Use In Commerce Date | Thursday, February 25, 2016 |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, November 17, 2021 |
| Primary Code | 042 |
| First Use Anywhere Date | Monday, February 11, 2008 |
| First Use In Commerce Date | Monday, February 11, 2008 |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, November 17, 2021 |
| Primary Code | 044 |
| First Use Anywhere Date | Thursday, February 25, 2016 |
| First Use In Commerce Date | Thursday, February 25, 2016 |
| Party Name | Precision BioSciences, Inc. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | Durham, NC 277013712 |
| Party Name | Precision BioSciences, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Durham, NC 277013712 |
| Party Name | Precision BioSciences, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Durham, NC 277013712 |
| Event Date | Event Description |
| Monday, May 8, 2023 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Monday, May 8, 2023 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Monday, May 8, 2023 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Monday, May 8, 2023 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Monday, May 8, 2023 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, April 25, 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, April 25, 2023 | REGISTERED-PRINCIPAL REGISTER |
| Monday, March 6, 2023 | ATTORNEY REVIEW COMPLETED |
| Monday, March 6, 2023 | LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN |
| Monday, March 6, 2023 | JURISDICTION RESTORED TO EXAMINING ATTORNEY |
| Wednesday, March 1, 2023 | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED |
| Wednesday, January 18, 2023 | EXTENSION OF TIME TO OPPOSE RECEIVED |
| Tuesday, December 20, 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, December 20, 2022 | PUBLISHED FOR OPPOSITION |
| Thursday, December 15, 2022 | LETTER OF PROTEST EVIDENCE FORWARDED |
| Wednesday, November 30, 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Thursday, November 17, 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, November 2, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, November 2, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, November 2, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, May 12, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, May 12, 2022 | NON-FINAL ACTION E-MAILED |
| Thursday, May 12, 2022 | NON-FINAL ACTION WRITTEN |
| Tuesday, May 10, 2022 | ASSIGNED TO EXAMINER |
| Wednesday, November 17, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Saturday, November 13, 2021 | NEW APPLICATION ENTERED |